RhCcEe抗原配合性血液输注在反复输血患者中的应用探讨  

Application of RhCcEe compatible blood transfusion in patients with repeated blood transfusion

作　　者：尹玉婷 喻斌[1] 伍庆辉 Yin Yu-ting;Yu Bin;Wu Qing-hui(Department of Blood Transfusion,Pingxiang People's Hospital,Pingxiang 337000,Jiangxi,China)

机构地区：[1]萍乡市人民医院输血科,江西萍乡337000

出　　处：《四川生理科学杂志》2024年第12期2611-2613,2635,共4页

基　　金：萍乡市科技计划项目(编号:2021PY079)。

摘　　要：目的:探讨RhCcEe抗原配合性血液输注在反复输血患者中的应用。方法:选取2022年1月至2023年6月66例在我院接受反复输血的患者作为研究对象,通过随机数表法将其分为对照组和实验组,每组患者数均为33例。对照组采取常规输血方法(ABO血型和RhD血型相符)进行输血,实验组则实施RhCcEe抗原配合性输血。观察两组患者新抗体产生情况、血液指标变化[红细胞计数(RBC)、血红蛋白水平(Hb)]并计算Hb升高预期值及输血不良反应发生率。结果:实验组新抗体产生率低于对照组(P<0.05);实验组只有1例输注红细胞后Hb未达到预期值,对照组有9例在多次输注红细胞后,Hb未达到预期目标,有5例甚至出现输血后复查Hb降低。实验组无效输注率为3.03%,远低于对照组的42.42%(x^(2)=14.580,P<0.05),且实验组患者输血后RBC、Hb指标水平均高于对照组;实验组不良反应少于对照组(P<0.05)。结论:RhCcEe抗原配合性血液输注在反复输血患者中能降低新抗体产生率,增强患者血液指标,减少不良反应的发生。Objective:To investigate the application of RhCcEe compatible blood transfusion in patients with repeated blood transfusion.Methods:Sixty-six patients who received repeated blood transfusion in the hospital from January 2022 to June 2023 were selected as the research subjects.Using the random number table,they were assigned to the control group(33 cases)and the experimental group(33 cases),receiving conventional blood transfusion(matching ABO and RhD blood types)and RhCcEe compatible blood transfusion,respectively.The production of new antibodies and changes in blood indicators[red blood cell count(RBC)and hemoglobin level(Hb)]in the two groups were observed.The expected increase in Hb and the incidence of adverse reactions to transfusion were calculated.Results:The production rate of new antibodies in the experimental group was lower than that in the control group(P<0.05).Only one case in the experimental group did not achieve the expected Hb value after red blood cell transfusion.Nine cases in the control group did not achieve the expected Hb value after multiple red blood cell transfusion,and five cases even showed a decrease in Hb after transfusion.The ineffective transfusion rate in the experimental group(3.03%)was much lower than that in the control group(42.42%)(x^(2)=14.580,P<0.05).The levels of RBC and Hb in the experimental group were higher than those in the control group after transfusion.The experimental group had fewer adverse reactions than the control group(P<0.05).Conclusion:RhCcEe compatible blood transfusion can reduce the production rate of new antibodies,improve blood indicators,and reduce the occurrence of adverse reactions in patients with repeated blood transfusion.

关 键 词：反复输血 RhCcEe抗原配合性 血液指标 不良反应 新抗体 

分 类 号：R457.1[医药卫生—治疗学]